Deals & IPOs

Astromech's $230 Million Form Bio Deal Tests Evolutionary AI

Astromech acquired Form Bio for $230 million in stock, pairing an evolutionary AI system still under development with tools used to design and manufacture gene-therapy vectors.

By Daniel Okafor

4 min read

Astromech Buys Form Bio to Combine Evolutionary AI and Genomic Design
Astromech Buys Form Bio to Combine Evolutionary AI and Genomic DesignPublicDomainPictures / pixabay

What's News

  • Astromech announced the $230 million all-stock Form Bio acquisition on November 17, 2026.
  • A promoter and nuclease redesign raised AAV full-genome content from 13% to 59% in one month.
  • Coding-sequence optimization alone raised full-genome content from about 2% to about 45% in a separate program.
  • Form Bio launched as a Colossal Biosciences spinout in September 2022; George Church and Ben Lamm co-founded Astromech.
  • Form Bio reported more than $40 million in venture financing, while Astromech reported more than $60 million.

By Daniel Okafor

Astromech announced a $230 million all-stock acquisition of Form Bio on November 17, 2026. The transaction adds Form Bio’s intellectual property, selected contracts and assets, and team, according to Astromech.

The deal combines Astromech’s evolutionary modeling with Form Bio’s AI tools for genetic-medicine design, vector optimization, manufacturing and genomic-quality assessment. The companies said researchers could move from evolutionary patterns to designing and testing genetic constructs in human therapeutics, genome engineering and animal health.

What does Form Bio bring to Astromech?

Form Bio co-founder and former CEO Andrew Busey has been named Astromech’s Chief AI Officer and Head of Technology, according to the acquisition announcement. Busey described Form Bio’s path from computational de-extinction work to foundation models for designing human therapeutics.

“Joining Astromech gives us the opportunity to build on that progress, bringing evolutionary insights into the design decisions we help researchers make,” Busey said.

Form Bio’s product materials describe three parts of its applied workflow:

  • FormSightAI screens thousands of vector designs in silico to identify candidates intended to improve yield and reduce contaminants.
  • FormManufacturing supports work from design through commercial release.
  • FormBatchQC provides lot-level analysis of contaminants and comparability.

Astromech and Form Bio said the connection could address quality challenges earlier in development. They aim to reduce unwanted components during design and potentially lessen downstream purification.

What design gains has Form Bio reported?

Form Bio’s October 6, 2025 partnership announcement with Cure Rare Disease reported a rise in AAV full-genome content from 13% to 59%. It credited promoter modification and nuclease optimization for the one-month gain in a Duchenne muscular dystrophy candidate. The work combined long-read sequencing, genome-integrity analysis, rational design, and AI and machine-learning models.

Astromech defines full-genome content as the proportion of capsids containing a full vector genome. The acquisition announcement calls that measure a critical quality attribute for regulatory approval. Cure Rare Disease said the work advanced the program to preclinical studies in living organisms. Astromech said the result concerns vector-manufacturing quality and preclinical progress, rather than clinical outcomes in patients.

The acquisition announcement also reported that coding-sequence optimization alone increased full-genome content from about 2% to about 45% in a separate program. It kept expression at baseline. The examples used distinct levers: Duchenne work changed the promoter and nuclease, while the separate program changed only the coding sequence.

Who uses Form Bio’s technology?

Form Bio’s capabilities support genetic-medicine programs at Eli Lilly, Stanford, Coave Therapeutics, Taysha Gene Therapies and Solid Biosciences, according to the acquisition announcement.

Both companies trace their roots to Colossal Biosciences, according to the announcement. Colossal developed Form Bio before launching it as a spinout in September 2022, when it focused on multi-species genome engineering. Form Bio later expanded into human genetic medicines, according to the announcement. Astromech emerged from Colossal’s comparative-genomics, ancient-DNA and computational-biology work. George Church and Ben Lamm co-founded Astromech, according to the announcement.

The announcement reports more than $40 million in venture financing for Form Bio and more than $60 million for Astromech.

Can evolutionary AI improve those gains?

Astromech’s technical description presents the Large Life Model as a system still under development. The model will combine attention-based deep learning with Bayesian reconstruction of ancestral sequences and regulatory states while learning across species and evolutionary time. Its listed architecture includes a graph-based pangenome that captures structural genetic variants across populations. It also includes a multi-omics integrator, also under development, for unified biological insight across complex systems.

The acquisition announcement leaves the central question open: whether evolutionary reconstruction can add measurable improvements to the design and manufacturing results Form Bio already reports. Form Bio’s 2025 results predate the acquisition and establish a baseline for its existing tools, not proof of the combined system.

The next proof point is a joint program showing that evolutionary modeling improves vector yield, contaminant levels or full-genome content beyond Form Bio’s reported results. Until Astromech produces that evidence, the $230 million stock deal links a model under development to applied tools but leaves the combined system’s manufacturing advantage unmeasured.

Source: unite.ai

Share this article:

More from Daniel Okafor

Daniel Okafor

Show full bio

Correspondent covering money, funding and market shifts around entrepreneurship, startups and venture funding at Business Bearings.

2,282 articles

Related articles

« Previous articleNext article »